<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:03:14 -0700</creation_date>
  <update_date>2013-04-11 15:15:55 -0600</update_date>
  <accession>HMDBP02173</accession>
  <secondary_accessions>
    <accession>7657</accession>
    <accession>HMDBP11387</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>Nuclear receptor subfamily 1 group C member 3</synonym>
    <synonym>PPAR-gamma</synonym>
  </synonyms>
  <gene_name>PPARG</gene_name>
  <general_function>Involved in DNA binding</general_function>
  <specific_function>Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00039</accession>
      <name>Butyric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01043</accession>
      <name>Arachidonic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05006</accession>
      <name>Atorvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05031</accession>
      <name>Rosiglitazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01338</accession>
      <name>Palmityl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06497</accession>
      <name>Heptadecanoyl CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01114</accession>
      <name>Stearoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04258</accession>
      <name>Eicosanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01206</accession>
      <name>Acetyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01275</accession>
      <name>Propionyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01088</accession>
      <name>Butyryl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13037</accession>
      <name>Pentanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12969</accession>
      <name>Heptanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01070</accession>
      <name>Octanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13028</accession>
      <name>Nonanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06404</accession>
      <name>Decanoyl-CoA (n-C10:0CoA)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13114</accession>
      <name>Undecanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03571</accession>
      <name>Lauroyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06526</accession>
      <name>Tetracosanoyl-CoA  </name>
    </metabolite>
    <metabolite>
      <accession>HMDB02009</accession>
      <name>Crotonoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01290</accession>
      <name>Glutaconyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03944</accession>
      <name>trans-2-Hexenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03949</accession>
      <name>(2E)-Octenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03948</accession>
      <name>(2E)-Decenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03946</accession>
      <name>(2E)-Tetradecenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04257</accession>
      <name>3Z-dodecenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03712</accession>
      <name>(2E)-Dodecenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01243</accession>
      <name>Isobutyryl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11660</accession>
      <name>2-Methylhexanoyl-CoA </name>
    </metabolite>
    <metabolite>
      <accession>HMDB01113</accession>
      <name>Isovaleryl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02057</accession>
      <name>Pristanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00910</accession>
      <name>Tridecanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00806</accession>
      <name>Myristic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00220</accession>
      <name>Palmitic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00827</accession>
      <name>Stearic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02212</accession>
      <name>Arachidic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02259</accession>
      <name>Heptadecanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00826</accession>
      <name>Pentadecanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01041</accession>
      <name>2-Methylbutyryl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02307</accession>
      <name>Acrylyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03945</accession>
      <name>(2E)-Hexadecenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06529</accession>
      <name>trans-Octadec-2-enoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02845</accession>
      <name>Hexanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01999</accession>
      <name>Eicosapentaenoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14389</accession>
      <name>Mesalazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14869</accession>
      <name>Nateglinide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14933</accession>
      <name>Sulfasalazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15048</accession>
      <name>Repaglinide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15101</accession>
      <name>Telmisartan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15149</accession>
      <name>Balsalazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15200</accession>
      <name>Glipizide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15264</accession>
      <name>Pioglitazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15382</accession>
      <name>Mitiglinide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15465</accession>
      <name>Bezafibrate</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>sequence-specific dna binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>zinc ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>steroid hormone receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>sequence-specific dna binding transcription factor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ligand-dependent nuclear receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleic acid binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>dna binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>biological regulation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of biological process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of macromolecule metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of gene expression</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of transcription</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of transcription, dna-dependent</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane-bounded organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intracellular membrane-bounded organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>nucleus</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Nucleus</subcellular_location>
    <subcellular_location>Cytoplasmic</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:3</chromosome_location>
    <locus>3p25</locus>
    <gene_sequence>&gt;1518 bp
ATGGGTGAAACTCTGGGAGATTCTCCTATTGACCCAGAAAGCGATTCCTTCACTGATACA
CTGTCTGCAAACATATCACAAGAAATGACCATGGTTGACACAGAGATGCCATTCTGGCCC
ACCAACTTTGGGATCAGCTCCGTGGATCTCTCCGTAATGGAAGACCACTCCCACTCCTTT
GATATCAAGCCCTTCACTACTGTTGACTTCTCCAGCATTTCTACTCCACATTACGAAGAC
ATTCCATTCACAAGAACAGATCCAGTGGTTGCAGATTACAAGTATGACCTGAAACTTCAA
GAGTACCAAAGTGCAATCAAAGTGGAGCCTGCATCTCCACCTTATTATTCTGAGAAGACT
CAGCTCTACAATAAGCCTCATGAAGAGCCTTCCAACTCCCTCATGGCAATTGAATGTCGT
GTCTGTGGAGATAAAGCTTCTGGATTTCACTATGGAGTTCATGCTTGTGAAGGATGCAAG
GGTTTCTTCCGGAGAACAATCAGATTGAAGCTTATCTATGACAGATGTGATCTTAACTGT
CGGATCCACAAAAAAAGTAGAAATAAATGTCAGTACTGTCGGTTTCAGAAATGCCTTGCA
GTGGGGATGTCTCATAATGCCATCAGGTTTGGGCGGATGCCACAGGCCGAGAAGGAGAAG
CTGTTGGCGGAGATCTCCAGTGATATCGACCAGCTGAATCCAGAGTCCGCTGACCTCCGG
GCCCTGGCAAAACATTTGTATGACTCATACATAAAGTCCTTCCCGCTGACCAAAGCAAAG
GCGAGGGCGATCTTGACAGGAAAGACAACAGACAAATCACCATTCGTTATCTATGACATG
AATTCCTTAATGATGGGAGAAGATAAAATCAAGTTCAAACACATCACCCCCCTGCAGGAG
CAGAGCAAAGAGGTGGCCATCCGCATCTTTCAGGGCTGCCAGTTTCGCTCCGTGGAGGCT
GTGCAGGAGATCACAGAGTATGCCAAAAGCATTCCTGGTTTTGTAAATCTTGACTTGAAC
GACCAAGTAACTCTCCTCAAATATGGAGTCCACGAGATCATTTACACAATGCTGGCCTCC
TTGATGAATAAAGATGGGGTTCTCATATCCGAGGGCCAAGGCTTCATGACAAGGGAGTTT
CTAAAGAGCCTGCGAAAGCCTTTTGGTGACTTTATGGAGCCCAAGTTTGAGTTTGCTGTG
AAGTTCAATGCACTGGAATTAGATGACAGCGACTTGGCAATATTTATTGCTGTCATTATT
CTCAGTGGAGACCGCCCAGGTTTGCTGAATGTGAAGCCCATTGAAGACATTCAAGACAAC
CTGCTACAAGCCCTGGAGCTCCAGCTGAAGCTGAACCACCCTGAGTCCTCACAGCTGTTT
GCCAAGCTGCTCCAGAAAATGACAGACCTCAGACAGATTGTCACGGAACACGTGCAGCTA
CTGCAGGTGATCAAGAAGACGGAGACAGACATGAGTCTTCACCCGCTCCTGCAGGAGATC
TACAAGGACTTGTACTAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>505</residue_number>
    <molecular_weight>57619.6</molecular_weight>
    <theoretical_pi>5.77</theoretical_pi>
    <pfams>
      <pfam>
        <name>Hormone_recep</name>
        <pfam_id>PF00104</pfam_id>
      </pfam>
      <pfam>
        <name>PPARgamma_N</name>
        <pfam_id>PF12577</pfam_id>
      </pfam>
      <pfam>
        <name>zf-C4</name>
        <pfam_id>PF00105</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>None</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Peroxisome proliferator-activated receptor gamma
MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDLSVMEDHSHSF
DIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKT
QLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIYDRCDLNC
RIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLR
ALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQE
QSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLAS
LMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVII
LSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQL
LQVIKKTETDMSLHPLLQEIYKDLY</protein_sequence>
  </protein_properties>
  <genbank_protein_id>86451955</genbank_protein_id>
  <uniprot_id>P37231</uniprot_id>
  <uniprot_name>PPARG_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1I7I</pdb_id>
  </pdb_ids>
  <genbank_gene_id>U79012</genbank_gene_id>
  <genecard_id>PPARG</genecard_id>
  <geneatlas_id>PPARG</geneatlas_id>
  <hgnc_id>HGNC:9236</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Mukherjee R, Jow L, Croston GE, Paterniti JR Jr: Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem. 1997 Mar 21;272(12):8071-6.</reference_text>
      <pubmed_id>9065481</pubmed_id>
    </reference>
    <reference>
      <reference_text>Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE, Berger J: Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun. 1996 Jul 16;224(2):431-7.</reference_text>
      <pubmed_id>8702406</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yanase T, Yashiro T, Takitani K, Kato S, Taniguchi S, Takayanagi R, Nawata H: Differential expression of PPAR gamma1 and gamma2 isoforms in human adipose tissue. Biochem Biophys Res Commun. 1997 Apr 17;233(2):320-4.</reference_text>
      <pubmed_id>9144532</pubmed_id>
    </reference>
    <reference>
      <reference_text>Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD: Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 1995;4(4-5):281-99.</reference_text>
      <pubmed_id>7787419</pubmed_id>
    </reference>
    <reference>
      <reference_text>Okazawa H, Mori H, Tamori Y, Araki S, Niki T, Masugi J, Kawanishi M, Kubota T, Shinoda H, Kasuga M: No coding mutations are detected in the peroxisome proliferator-activated receptor-gamma gene in Japanese patients with lipoatrophic diabetes. Diabetes. 1997 Nov;46(11):1904-6.</reference_text>
      <pubmed_id>9356045</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lambe KG, Tugwood JD: A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem. 1996 Jul 1;239(1):1-7.</reference_text>
      <pubmed_id>8706692</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Muzny DM, Scherer SE, Kaul R, Wang J, Yu J, Sudbrak R, Buhay CJ, Chen R, Cree A, Ding Y, Dugan-Rocha S, Gill R, Gunaratne P, Harris RA, Hawes AC, Hernandez J, Hodgson AV, Hume J, Jackson A, Khan ZM, Kovar-Smith C, Lewis LR, Lozado RJ, Metzker ML, Milosavljevic A, Miner GR, Morgan MB, Nazareth LV, Scott G, Sodergren E, Song XZ, Steffen D, Wei S, Wheeler DA, Wright MW, Worley KC, Yuan Y, Zhang Z, Adams CQ, Ansari-Lari MA, Ayele M, Brown MJ, Chen G, Chen Z, Clendenning J, Clerc-Blankenburg KP, Chen R, Chen Z, Davis C, Delgado O, Dinh HH, Dong W, Draper H, Ernst S, Fu G, Gonzalez-Garay ML, Garcia DK, Gillett W, Gu J, Hao B, Haugen E, Havlak P, He X, Hennig S, Hu S, Huang W, Jackson LR, Jacob LS, Kelly SH, Kube M, Levy R, Li Z, Liu B, Liu J, Liu W, Lu J, Maheshwari M, Nguyen BV, Okwuonu GO, Palmeiri A, Pasternak S, Perez LM, Phelps KA, Plopper FJ, Qiang B, Raymond C, Rodriguez R, Saenphimmachak C, Santibanez J, Shen H, Shen Y, Subramanian S, Tabor PE, Verduzco D, Waldron L, Wang J, Wang J, Wang Q, Williams GA, Wong GK, Yao Z, Zhang J, Zhang X, Zhao G, Zhou J, Zhou Y, Nelson D, Lehrach H, Reinhardt R, Naylor SL, Yang H, Olson M, Weinstock G, Gibbs RA: The DNA sequence, annotation and analysis of human chromosome 3.  Nature. 2006 Apr 27;440(7088):1194-8.</reference_text>
      <pubmed_id>16641997</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Caira F, Antonson P, Pelto-Huikko M, Treuter E, Gustafsson JA: Cloning and characterization of RAP250, a novel nuclear receptor coactivator. J Biol Chem. 2000 Feb 25;275(8):5308-17.</reference_text>
      <pubmed_id>10681503</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhou XP, Smith WM, Gimm O, Mueller E, Gao X, Sarraf P, Prior TW, Plass C, von Deimling A, Black PM, Yates AJ, Eng C: Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population. J Med Genet. 2000 Jun;37(6):410-4.</reference_text>
      <pubmed_id>10851250</pubmed_id>
    </reference>
    <reference>
      <reference_text>Shao W, Halachmi S, Brown M: ERAP140, a conserved tissue-specific nuclear receptor coactivator.  Mol Cell Biol. 2002 May;22(10):3358-72.</reference_text>
      <pubmed_id>11971969</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bu H, Kashireddy P, Chang J, Zhu YT, Zhang Z, Zheng W, Rao SM, Zhu YJ: ERBP, a novel estrogen receptor binding protein enhancing the activity of estrogen receptor. Biochem Biophys Res Commun. 2004 Apr 23;317(1):54-9.</reference_text>
      <pubmed_id>15047147</pubmed_id>
    </reference>
    <reference>
      <reference_text>Drori S, Girnun GD, Tou L, Szwaya JD, Mueller E, Xia K, Shivdasani RA, Spiegelman BM: Hic-5 regulates an epithelial program mediated by PPARgamma.  Genes Dev. 2005 Feb 1;19(3):362-75.</reference_text>
      <pubmed_id>15687259</pubmed_id>
    </reference>
    <reference>
      <reference_text>Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A: Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J Biol Chem. 1998 Nov 20;273(47):31108-12.</reference_text>
      <pubmed_id>9813012</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV: Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 1998 Sep 10;395(6698):137-43.</reference_text>
      <pubmed_id>9744270</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gampe RT Jr, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, Xu HE: Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell. 2000 Mar;5(3):545-55.</reference_text>
      <pubmed_id>10882139</pubmed_id>
    </reference>
    <reference>
      <reference_text>Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM: Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13919-24. Epub 2001 Nov 6.</reference_text>
      <pubmed_id>11698662</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cronet P, Petersen JF, Folmer R, Blomberg N, Sjoblom K, Karlsson U, Lindstedt EL, Bamberg K: Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure. 2001 Aug;9(8):699-706.</reference_text>
      <pubmed_id>11587644</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ebdrup S, Pettersson I, Rasmussen HB, Deussen HJ, Frost Jensen A, Mortensen SB, Fleckner J, Pridal L, Nygaard L, Sauerberg P: Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. J Med Chem. 2003 Apr 10;46(8):1306-17.</reference_text>
      <pubmed_id>12672231</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ostberg T, Svensson S, Selen G, Uppenberg J, Thor M, Sundbom M, Sydow-Backman M, Gustavsson AL, Jendeberg L: A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem. 2004 Sep 24;279(39):41124-30. Epub 2004 Jul 15.</reference_text>
      <pubmed_id>15258145</pubmed_id>
    </reference>
    <reference>
      <reference_text>Haffner CD, Lenhard JM, Miller AB, McDougald DL, Dwornik K, Ittoop OR, Gampe RT Jr, Xu HE, Blanchard S, Montana VG, Consler TG, Bledsoe RK, Ayscue A, Croom D: Structure-based design of potent retinoid X receptor alpha agonists.  J Med Chem. 2004 Apr 8;47(8):2010-29.</reference_text>
      <pubmed_id>15056000</pubmed_id>
    </reference>
    <reference>
      <reference_text>Shi GQ, Dropinski JF, McKeever BM, Xu S, Becker JW, Berger JP, MacNaul KL, Elbrecht A, Zhou G, Doebber TW, Wang P, Chao YS, Forrest M, Heck JV, Moller DE, Jones AB: Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity. J Med Chem. 2005 Jun 30;48(13):4457-68.</reference_text>
      <pubmed_id>15974597</pubmed_id>
    </reference>
    <reference>
      <reference_text>Li Y, Choi M, Suino K, Kovach A, Daugherty J, Kliewer SA, Xu HE: Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner. Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9505-10. Epub 2005 Jun 23.</reference_text>
      <pubmed_id>15976031</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hopkins CR, O'neil SV, Laufersweiler MC, Wang Y, Pokross M, Mekel M, Evdokimov A, Walter R, Kontoyianni M, Petrey ME, Sabatakos G, Roesgen JT, Richardson E, Demuth TP Jr: Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5659-63. Epub 2006 Aug 21.</reference_text>
      <pubmed_id>16919947</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mahindroo N, Wang CC, Liao CC, Huang CF, Lu IL, Lien TW, Peng YH, Huang WJ, Lin YT, Hsu MC, Lin CH, Tsai CH, Hsu JT, Chen X, Lyu PC, Chao YS, Wu SY, Hsieh HP: Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies. J Med Chem. 2006 Feb 9;49(3):1212-6.</reference_text>
      <pubmed_id>16451087</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lu IL, Huang CF, Peng YH, Lin YT, Hsieh HP, Chen CT, Lien TW, Lee HJ, Mahindroo N, Prakash E, Yueh A, Chen HY, Goparaju CM, Chen X, Liao CC, Chao YS, Hsu JT, Wu SY: Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. J Med Chem. 2006 May 4;49(9):2703-12.</reference_text>
      <pubmed_id>16640330</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR: Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun. 1997 Dec 18;241(2):270-4.</reference_text>
      <pubmed_id>9425261</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR: Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med. 1998 Oct 1;339(14):953-9.</reference_text>
      <pubmed_id>9753710</pubmed_id>
    </reference>
    <reference>
      <reference_text>Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998 Nov;20(3):284-7.</reference_text>
      <pubmed_id>9806549</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hamann A, Munzberg H, Buttron P, Busing B, Hinney A, Mayer H, Siegfried W, Hebebrand J, Greten H: Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects. Eur J Endocrinol. 1999 Jul;141(1):90-2.</reference_text>
      <pubmed_id>10407229</pubmed_id>
    </reference>
    <reference>
      <reference_text>Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS, Auwerx J, Uusitupa M, Laakso M: Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab. 1999 Oct;84(10):3708-12.</reference_text>
      <pubmed_id>10523018</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C: Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell. 1999 Jun;3(6):799-804.</reference_text>
      <pubmed_id>10394368</pubmed_id>
    </reference>
    <reference>
      <reference_text>Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S: Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999 Dec 23-30;402(6764):880-3.</reference_text>
      <pubmed_id>10622252</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hegele RA, Cao H, Frankowski C, Mathews ST, Leff T: PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes. 2002 Dec;51(12):3586-90.</reference_text>
      <pubmed_id>12453919</pubmed_id>
    </reference>
    <reference>
      <reference_text>Agarwal AK, Garg A: A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab. 2002 Jan;87(1):408-11.</reference_text>
      <pubmed_id>11788685</pubmed_id>
    </reference>
    <reference>
      <reference_text>Masud S, Ye S: Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet. 2003 Oct;40(10):773-80.</reference_text>
      <pubmed_id>14569127</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temelkova-Kurktschiev T, Hanefeld M, Chinetti G, Zawadzki C, Haulon S, Kubaszek A, Koehler C, Leonhardt W, Staels B, Laakso M: Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab. 2004 Sep;89(9):4238-42.</reference_text>
      <pubmed_id>15356014</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kim KS, Choi SM, Shin SU, Yang HS, Yoon Y: Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects. Metabolism. 2004 Dec;53(12):1538-43.</reference_text>
      <pubmed_id>15562396</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kim HJ, Woo IS, Kang ES, Eun SY, Kim HJ, Lee JH, Chang KC, Kim JH, Seo HG: Identification of a truncated alternative splicing variant of human PPARgamma1 that exhibits dominant negative activity. Biochem Biophys Res Commun. 2006 Sep 1;347(3):698-706. Epub 2006 Jul 5.</reference_text>
      <pubmed_id>16842753</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Butyric acid</name>
        <accession>HMDB00039</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab M, Reynders V, Ulrich S, Zahn N, Stein J, Schroder O: PPARgamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis. 2006 Oct;11(10):1801-11.</reference_text>
        <pubmed_id>16927016</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Eicosapentaenoic acid</name>
        <accession>HMDB01999</accession>
      </metabolite>
      <reference>
        <reference_text>Chambrier C, Bastard JP, Rieusset J, Chevillotte E, Bonnefont-Rousselot D, Therond P, Hainque B, Riou JP, Laville M, Vidal H: Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma. Obes Res. 2002 Jun;10(6):518-25.</reference_text>
        <pubmed_id>12055328</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Eicosapentaenoic acid</name>
        <accession>HMDB01999</accession>
      </metabolite>
      <reference>
        <reference_text>Selvaraj RK, Klasing KC: Lutein and eicosapentaenoic acid interact to modify iNOS mRNA levels through the PPARgamma/RXR pathway in chickens and HD11 cell lines. J Nutr. 2006 Jun;136(6):1610-6.</reference_text>
        <pubmed_id>16702329</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Eicosapentaenoic acid</name>
        <accession>HMDB01999</accession>
      </metabolite>
      <reference>
        <reference_text>Iwata Y, Miyamoto S, Takamura M, Yanagisawa H, Kasuya A: Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione. J Mol Graph Model. 2001;19(6):536-42, 598-600.</reference_text>
        <pubmed_id>11552681</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Eicosapentaenoic acid</name>
        <accession>HMDB01999</accession>
      </metabolite>
      <reference>
        <reference_text>Horia E, Watkins BA: Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis. 2007 Apr;28(4):809-15. Epub 2006 Oct 19.</reference_text>
        <pubmed_id>17052999</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Eicosapentaenoic acid</name>
        <accession>HMDB01999</accession>
      </metabolite>
      <reference>
        <reference_text>Ramakers JD, Mensink RP, Schaart G, Plat J: Arachidonic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-kappaB and elevates ICAM-1 expression in Caco-2 cells. Lipids. 2007 Aug;42(8):687-98. Epub 2007 Jul 3.</reference_text>
        <pubmed_id>17610002</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mesalazine</name>
        <accession>HMDB14389</accession>
      </metabolite>
      <reference>
        <reference_text>Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005 Apr 18;201(8):1205-15. Epub 2005 Apr 11.</reference_text>
        <pubmed_id>15824083</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mesalazine</name>
        <accession>HMDB14389</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O, Stein J: PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis. 2008 Jul;29(7):1407-14. Epub 2008 Jun 9.</reference_text>
        <pubmed_id>18544567</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mesalazine</name>
        <accession>HMDB14389</accession>
      </metabolite>
      <reference>
        <reference_text>Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12.</reference_text>
        <pubmed_id>18077625</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mesalazine</name>
        <accession>HMDB14389</accession>
      </metabolite>
      <reference>
        <reference_text>Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9.</reference_text>
        <pubmed_id>16939423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nateglinide</name>
        <accession>HMDB14869</accession>
      </metabolite>
      <reference>
        <reference_text>Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, Albrecht H, Schwede T, Meyer UA, Rucker C: Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol Pharmacol. 2007 Feb;71(2):398-406. Epub 2006 Nov 2.</reference_text>
        <pubmed_id>17082235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005 Apr 18;201(8):1205-15. Epub 2005 Apr 11.</reference_text>
        <pubmed_id>15824083</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O, Stein J: PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis. 2008 Jul;29(7):1407-14. Epub 2008 Jun 9.</reference_text>
        <pubmed_id>18544567</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12.</reference_text>
        <pubmed_id>18077625</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9.</reference_text>
        <pubmed_id>16939423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Repaglinide</name>
        <accession>HMDB15048</accession>
      </metabolite>
      <reference>
        <reference_text>Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, Albrecht H, Schwede T, Meyer UA, Rucker C: Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol Pharmacol. 2007 Feb;71(2):398-406. Epub 2006 Nov 2.</reference_text>
        <pubmed_id>17082235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telmisartan</name>
        <accession>HMDB15101</accession>
      </metabolite>
      <reference>
        <reference_text>Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009 Feb;150(2):862-70. Epub 2009 Jan 15.</reference_text>
        <pubmed_id>19147680</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telmisartan</name>
        <accession>HMDB15101</accession>
      </metabolite>
      <reference>
        <reference_text>Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006 Oct 1;72(1):184-90. Epub 2006 Jul 21.</reference_text>
        <pubmed_id>16938288</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telmisartan</name>
        <accession>HMDB15101</accession>
      </metabolite>
      <reference>
        <reference_text>Kurtz TW: Beyond the classic angiotensin-receptor-blocker profile.  Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S19-26.</reference_text>
        <pubmed_id>18580862</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telmisartan</name>
        <accession>HMDB15101</accession>
      </metabolite>
      <reference>
        <reference_text>Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses. 2005;64(3):476-8.</reference_text>
        <pubmed_id>15617852</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telmisartan</name>
        <accession>HMDB15101</accession>
      </metabolite>
      <reference>
        <reference_text>Kurtz TW: Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005 Apr;42 Suppl 1:S9-16.</reference_text>
        <pubmed_id>15868121</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telmisartan</name>
        <accession>HMDB15101</accession>
      </metabolite>
      <reference>
        <reference_text>Yamagishi S, Nakamura K, Matsui T: Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007 Aug;7(5):463-9.</reference_text>
        <pubmed_id>17691961</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telmisartan</name>
        <accession>HMDB15101</accession>
      </metabolite>
      <reference>
        <reference_text>Yamagishi S, Takenaka K, Inoue H: Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Med Hypotheses. 2006;66(1):118-20. Epub 2005 Sep 12.</reference_text>
        <pubmed_id>16154710</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Balsalazide</name>
        <accession>HMDB15149</accession>
      </metabolite>
      <reference>
        <reference_text>Tursi A: Balsalazide in treating colonic diseases.  Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1555-63.</reference_text>
        <pubmed_id>19708827</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Balsalazide</name>
        <accession>HMDB15149</accession>
      </metabolite>
      <reference>
        <reference_text>Iacucci M, de Silva S, Ghosh S: Mesalazine in inflammatory bowel disease: a trendy topic once again?  Can J Gastroenterol. 2010 Feb;24(2):127-33.</reference_text>
        <pubmed_id>20151072</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Balsalazide</name>
        <accession>HMDB15149</accession>
      </metabolite>
      <reference>
        <reference_text>Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9.</reference_text>
        <pubmed_id>16939423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Balsalazide</name>
        <accession>HMDB15149</accession>
      </metabolite>
      <reference>
        <reference_text>Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12.</reference_text>
        <pubmed_id>18077625</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glipizide</name>
        <accession>HMDB15200</accession>
      </metabolite>
      <reference>
        <reference_text>Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, Albrecht H, Schwede T, Meyer UA, Rucker C: Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol Pharmacol. 2007 Feb;71(2):398-406. Epub 2006 Nov 2.</reference_text>
        <pubmed_id>17082235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pioglitazone</name>
        <accession>HMDB15264</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pioglitazone</name>
        <accession>HMDB15264</accession>
      </metabolite>
      <reference>
        <reference_text>Sugii S, Olson P, Sears DD, Saberi M, Atkins AR, Barish GD, Hong SH, Castro GL, Yin YQ, Nelson MC, Hsiao G, Greaves DR, Downes M, Yu RT, Olefsky JM, Evans RM: PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization. Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22504-9. Epub 2009 Dec 16.</reference_text>
        <pubmed_id>20018750</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pioglitazone</name>
        <accession>HMDB15264</accession>
      </metabolite>
      <reference>
        <reference_text>Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA: Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9.</reference_text>
        <pubmed_id>15356026</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pioglitazone</name>
        <accession>HMDB15264</accession>
      </metabolite>
      <reference>
        <reference_text>Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953-6.</reference_text>
        <pubmed_id>7768881</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pioglitazone</name>
        <accession>HMDB15264</accession>
      </metabolite>
      <reference>
        <reference_text>Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.  Diabetes. 1998 Apr;47(4):507-14.</reference_text>
        <pubmed_id>9568680</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pioglitazone</name>
        <accession>HMDB15264</accession>
      </metabolite>
      <reference>
        <reference_text>Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996 Feb 2;39(3):665-8.</reference_text>
        <pubmed_id>8576907</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitiglinide</name>
        <accession>HMDB15382</accession>
      </metabolite>
      <reference>
        <reference_text>Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, Albrecht H, Schwede T, Meyer UA, Rucker C: Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol Pharmacol. 2007 Feb;71(2):398-406. Epub 2006 Nov 2.</reference_text>
        <pubmed_id>17082235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bezafibrate</name>
        <accession>HMDB15465</accession>
      </metabolite>
      <reference>
        <reference_text>Tenenbaum A, Motro M, Fisman EZ: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol. 2005 Sep 16;4:14.</reference_text>
        <pubmed_id>16168052</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
